The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Mechanisms of resistance to ADCs and overcoming them
Samreen Ahmed, FRCP, MD, MBBS, MSc, University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the mechanisms of resistance to antibody-drug conjugates (ADCs) and how these insights have driven drug development. She explains the importance of ADCs in delivering potent chemotherapy directly into cancer cells and highlights resistance mechanisms, including receptor mutations, loss of target receptors, and challenges in ADC internalization. Advances such as cleavable linkers and the bystander effect have significantly improved ADC efficacy, allowing chemotherapy to impact even heterogeneous tumors. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
